moatshark My

All holdings

Amgen

AMGN

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
5
In their latest 13F (Q3 2026)
See who
Value held
$290m
Combined value at quarter end
Last quarter
0 bought
5 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q3 ’26 end
$421.51
+16.4% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-19.1%Q4 ’24
+19.5%Q1 ’25
-10.4%Q2 ’25
+1.1%Q3 ’25
+16.0%Q4 ’25
+7.5%Q1 ’26
+2.9%Q2 ’26
+16.4%Q3 ’26
Q4 ’24: -19.1%; Q1 ’25: +19.5%; Q2 ’25: -10.4%; Q3 ’25: +1.1%; Q4 ’25: +16.0%; Q1 ’26: +7.5%; Q2 ’26: +2.9%; Q3 ’26: +16.4%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

5Q4 ’23
5Q1 ’24
5Q2 ’24
5Q3 ’24
5Q4 ’24
5Q1 ’25
5Q2 ’25
5Q3 ’25
5Q4 ’25
5Q1 ’26
5Q2 ’26
2Q3 ’26
Q4 ’23: 5; Q1 ’24: 5; Q2 ’24: 5; Q3 ’24: 5; Q4 ’24: 5; Q1 ’25: 5; Q2 ’25: 5; Q3 ’25: 5; Q4 ’25: 5; Q1 ’26: 5; Q2 ’26: 5; Q3 ’26: 2

Counts the managers on this site whose 13F for that quarter includes Amgen.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Amgen
Smead Capital Management5.3%$247m$247mTrimmed -11%41 qtrs
Matrix Asset Advisors2.9%$35.4m$35.4mTrimmed -18%23 qtrs
Mairs & Power0.0%$1.8m$1.8mTrimmed -0.8%53 qtrs
Horizon Kinetics0.0%$833k$833kTrimmed -4.1%29 qtrs
Dodge & Cox0.0%$4.6m$4.6mTrimmed -4.1%53 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Amgen
Bought or soldFiling
13 Aug 2026Khosla RachnaSVP, Business Development▼ Sold1,252$416.43$521kForm 4
11 Aug 2026Khosla RachnaSVP, Business Development▼ Sold2,000$412.57$825kForm 4
6 Aug 2026Miller DerekSVP, Human Resources▼ Sold2,069$402.54$833kForm 4
6 Aug 2026Grygiel Nancy A.SVP & CCO▼ Sold1,970$402.16$792kForm 4
6 Aug 2026Miller DerekSVP, Human Resources▼ Sold1,821$402.54$733kForm 4
6 Aug 2026Grygiel Nancy A.SVP & CCO▼ Sold1,000$402.16$402kForm 4

About the company

Sector
Health care · Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
541m at 30 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$19bn2013
$22bn2015
$23bn2017
$23bn2019
$26bn2021
$28bn2023
$37bn2025
2013: $19bn; 2014: $20bn; 2015: $22bn; 2016: $23bn; 2017: $23bn; 2018: $24bn; 2019: $23bn; 2020: $25bn; 2021: $26bn; 2022: $26bn; 2023: $28bn; 2024: $33bn; 2025: $37bn
Amgen revenue and net income by year
YearRevenueNet income
2025$37bn$7.7bn
2024$33bn$4.1bn
2023$28bn$6.7bn
2022$26bn$6.6bn
2021$26bn$5.9bn
2020$25bn$7.3bn
2019$23bn$7.8bn
2018$24bn$8.4bn
2017$23bn$2.0bn
2016$23bn$7.7bn
2015$22bn$6.9bn
2014$20bn$5.2bn
2013$19bn$5.1bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Amgen, from their latest N-PORT filings.

Funds holding Amgen
Smead Value FundSmead Capital Management4.7%$184m29 May 2026